ReviewTherapeutics and clinical risk management2014
Current and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis).
Review in Therapeutics and clinical risk management, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Ocular and orbital manifestations of granulomatosis with polyangiitis: a systematic review of published cases.Romanian journal of ophthalmologyPooled it
- Beyond Infection and Malignancy: Diagnostic Pitfalls in Pulmonary Granulomatosis with Polyangiitis.Cureus · 2026Article
- Article
- Acute Pancreatitis as a First Presentation of Granulomatosis With Polyangiitis.ACG case reports journal · 2023Article
- The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review.Biology · 2022Review
- Case Report: Peripheral Ulcerative Keratitis in Systemic Solid Tumour Malignancies.Frontiers in medicine · 2022Article
- Multiple Bullous and Ulcers as Cutaneous Manifestations of Wegener's Granulomatosis: A Rare Case Report.Clinical, cosmetic and investigational dermatology · 2022Article
- Life-Threatening Subglottic Stenosis of Granulomatosis with Polyangiitis: A Case Report.Medicina (Kaunas, Lithuania) · 2021Article
- Recalcitrant infective scleritis masquerading an autoimmune necrotising scleritis: a primary presentation of biopsy-proven granulomatosis with polyangiitis.BMJ case reports · 2021Article
- The role of surgery in antineutrophil cytoplasmic antibody-associated vasculitides affecting the nose and sinuses: A systematic review.SAGE open medicine · 2020Review
- Temporal and Cartographic Analyses of the Distribution within Spain of Mortality Due to Granulomatosis with Polyangiitis (1984⁻2016).International journal of environmental research and public health · 2019Article
- Costs of Disease Relapses Among Individuals with Granulomatosis, with Polyangiitis, or Microscopic Polyangiitis in the United States.Rheumatology and therapy · 2018Article
- Peripheral Ulcerative Keratitis Associated with Autoimmune Disease: Pathogenesis and Treatment.Journal of ophthalmology · 2017Review
- Granulomatosis with polyangiitis (Wegener's disease): An updated review of ocular disease manifestations.Intractable & rare diseases research · 2016Review
- Fatal pulmonary complication during induction therapy in a patient with ANCA-associated vasculitis.Acta medica Lituanic · 2016Article
- Article
- Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.Drug design, development and therapy · 2015Review
- Peripheral Ulcerative Keratitis: A Review.Journal of ophthalmic & vision researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Granulomatosis with polyangiitis (GPA, formerly Wegener's granulomatosis) is a multisystem autoimmune condition associated with anti-neutrophil cytoplasm antibodies. Management of GPA can be complex, owing to the sometimes fulminant and multisystem nature of the presentation, the age demographics of the affected population, and a significant incidence of disease relapse. In this paper, we discuss how some of the challenges in the management of GPA have been and continue to be addressed including: reducing the toxicity of induction therapy; developing biomarkers to determine who can safely stop maintenance immunosuppression; improving the efficacy of maintenance therapy for relapsing patients; managing localized disease; and management of disease and treatment-associated comorbidity. Consideration is also given to emerging therapeutics in the treatment of GPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.